Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder

Yamamura, 2019, Trial of Satralizumab in neuromyelitis optica spectrum disorder, N. Engl. J. Med., 381, 2114, 10.1056/NEJMoa1901747 Fujihara, 2020, Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology, Neurol. Neuroimmunol. Neuroinflamm., 7, 10.1212/NXI.0000000000000841 Rose-John, 2012, IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6, Int. J. Biol. Sci., 8, 1237, 10.7150/ijbs.4989 Rose-John, 2021, Blocking only the bad side of IL-6 in inflammation and cancer, Cytokine, 148, 10.1016/j.cyto.2021.155690 Schreiber, 2021, Therapeutic Interleukin-6 trans-signaling inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease, Gastroenterology, 160, 2354, 10.1053/j.gastro.2021.02.062 Traboulsee, 2022, Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial, Lancet Neurol., 19, 402, 10.1016/S1474-4422(20)30078-8